Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New contraceptive device under attack:

This article was originally published in Clinica

Executive Summary

Unipath has admitted that around 450 women have become pregnant while using the company's Persona contraceptive device, hailed as a rival to the pill at its launch last September 30th. The device, which has been bought by more than 100,000 women from Boots chemists, measures hormone levels in urine to establish when a woman is fertile (see Clinica No 726, p 17). Unipath has recently reduced its claimed success rate for Persona from 95% to 94%, it told the BBC's Watchdog Healthcare programme. Clinica estimates the failure rate at 1.8%.

You may also be interested in...



Pfizer And Moderna Under Pressure To Agree Vaccine Supplies For Developing Nations

As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.

FDA Releases Final Guidance For Complex ANDA Meetings

The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.

UK Government Backs Vitamin D COVID Benefits With Supplement Handout

By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.

Topics

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel